Ind-Swift Laboratories Limited (BOM:532305)

Market Cap	11.10B +76.7%
Revenue (ttm)	5.94B +28.1%
Net Income	2.49B -29.8%
EPS	31.33 -47.8%
Shares Out	n/a
PE Ratio	4.47
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	22,804
Average Volume	61,973
Open	135.95
Previous Close	135.10
Day's Range	131.30 - 140.70
52-Week Range	67.15 - 143.00
Beta	n/a
RSI	72.60
Earnings Date	Jan 31, 2026

About Ind-Swift Laboratories

Ind-Swift Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, Parkinson’s disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, alcohol abstinence, antineoplastic, ADHD symptoms, anticance...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 1995
• Employees: 1,246
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 532305

Financial Performance

In fiscal year 2025, Ind-Swift Laboratories's revenue was 5.62 billion, a decrease of -67.13% compared to the previous year's 17.09 billion. Earnings were 2.50 billion, a decrease of -53.51%.